Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Shanghai Henlius Biotech
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05092815CT.gov The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Erdheim-Chester Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| hlx208 (this asset) | Shanghai Henlius Biotech | P2 | CCC · 53 |
| Cobimetinib | Cancer Research UK | P2/3 | B |
| Dabrafenib | Cancer Research UK | P2/3 | B |
| Trametinib | Cancer Research UK | P2/3 | B |
| Vemurafenib | Cancer Research UK | P2/3 | CCC |
| hh2710 | Haihe Biopharma Co., Ltd. | P1/2 | CCC |
| Valproic Acid | M.D. Anderson Cancer Center | P1 | CC |
| q702 | Mayo Clinic | P1 | CC |
| Temsirolimus | M.D. Anderson Cancer Center | P1 | CC |
+2 more in the Erdheim-Chester Disease cohort
Other indications for hlx208
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | B · 56 |
| Langerhans Cell Histiocytosis | — | P2 | CCC · 53 |
| Melanoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. hlx208 in Erdheim-Chester Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hlx208-erdheim-chester-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →